Pharmaceutical News

RSS

Researchers find new strategy that has potential to change standard of care for DLBCL patients

Patients with an aggressive lymphoma that often relapses and kills within two years experienced a remission of their cancer and stayed disease-free as long as 28 months after taking a commercially-available drug that made chemotherapy more effective.

20 Aug 2013

Phase III trial evaluates impact of Wisconsin Ginseng on fatigue levels of cancer patients

Millions of cancer patients find themselves exhausted completing the most mundane of tasks, and extra sleep doesn't seem to help. Today, they find hope in a supplement that medical researchers have shown to be effective in boosting their energy levels: Wisconsin Ginseng.

20 Aug 2013

NCI-PCPT explores survival of men on finasteride drug

In the NCI-sponsored Prostate Cancer Prevention Trial (PCPT), initial findings from a decade ago showed that the drug finasteride significantly reduced the risk of prostate cancer, but among those who did develop prostate cancer, paradoxically, the drug was associated with an increased risk of high-grade disease.

20 Aug 2013

Evidence shows bevacizumab therapy improves survival in patients with glioblastoma

A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.

20 Aug 2013

Tigercat and Velocity Pharmaceutical announce submission of IND application to FDA for VPD-737

Velocity Pharmaceutical Development, LLC ("VPD") and Tigercat Pharma, Inc., ("Tigercat") announced today the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for VPD-737 for the treatment of chronic pruritus.

19 Aug 2013

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to ALN-AT3 as a therapeutic for the treatment of hemophilia B.

17 Aug 2013

Older heart patients present unique challenges for determining optimal dosages of medications

Older heart patients present unique challenges for determining the optimal dosages of medications, so a new study from researchers at Duke Medicine offers some rare clarity about the use of drugs that are used to treat patients with heart attacks.

17 Aug 2013

Arrays of nanoscale sensors detect flaws in drugs and help improve production

MIT chemical engineers have discovered that arrays of billions of nanoscale sensors have unique properties that could help pharmaceutical companies produce drugs - especially those based on antibodies - more safely and efficiently.

17 Aug 2013

DLBCLs resistant to chemotherapy can be reprogrammed to respond using azacitidine

A phase I clinical trial showed diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy can be reprogrammed to respond to treatment using the drug azacitidine, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

17 Aug 2013

Kinetin stops the effects of Parkinson's disease on brain cells, say scientists

The active ingredient in an over-the-counter skin cream might do more than prevent wrinkles. Scientists have discovered that the drug, called kinetin, also slows or stops the effects of Parkinson's disease on brain cells.

16 Aug 2013

Scientists uncover potential drug target for effective therapy against bacterial disease brucellosis

UC Davis scientists have uncovered a potential drug target for the development of an effective therapy against the debilitating, chronic form of the bacterial disease brucellosis, which primarily afflicts people in Mediterranean and Middle Eastern countries.

16 Aug 2013

Researchers develop new method that creates libraries of drug candidates, accelerate drug discovery

James Bond had his reasons for ordering his martinis "shaken, not stirred." Similarly, drug manufacturers need to make sure the molecules in a new drug are arranged in an exact manner, lest there be dire consequences. Specifically, they need to be wary of enantiomers, mirror-image molecules composed of the same atoms, but arranged differently.

16 Aug 2013

Preventive antibiotics for HIV patients lower risk of TB or death

As part of the largest international research effort ever made to combat tuberculosis, a team of Johns Hopkins and Brazilian experts has found that preventive antibiotic therapy for people with HIV lowers this group's chances of developing TB or dying.

16 Aug 2013

Neurologists appear unaware of serious safety risks associated with anti-epilepsy drugs

A study by Johns Hopkins researchers shows that a fifth of U.S. neurologists appear unaware of serious drug safety risks associated with various anti-epilepsy drugs, potentially jeopardizing the health of patients who could be just as effectively treated with safer alternative medications.

16 Aug 2013

A*STAR's SIgN discovers new strategy to develop universal dengue vaccine

A new strategy that cripples the ability of the dengue virus to escape the host immune system has been discovered by A*STAR's Singapore Immunology Network. This breakthrough strategy opens a door of hope to what may become the world's first universal dengue vaccine candidate that can give full protection from all four serotypes of the dreadful virus.

14 Aug 2013

Coalition with Innovative Life Sciences delivers best medicine in oncology for cancer patients

GenoSpace, PathGroup and the IP & Science business of Thomson Reuters today announced an innovative initiative to develop and deliver a best-in-class personalized medicine service in oncology, the result of which will enable physicians to make more precise therapeutic recommendations for cancer patients.

13 Aug 2013

Pharmaceutical News

Researchers find new strategy that has potential to change standard of care for DLBCL patients

Phase III trial evaluates impact of Wisconsin Ginseng on fatigue levels of cancer patients

NCI-PCPT explores survival of men on finasteride drug

Evidence shows bevacizumab therapy improves survival in patients with glioblastoma

Tigercat and Velocity Pharmaceutical announce submission of IND application to FDA for VPD-737

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

Older heart patients present unique challenges for determining optimal dosages of medications

Arrays of nanoscale sensors detect flaws in drugs and help improve production

DLBCLs resistant to chemotherapy can be reprogrammed to respond using azacitidine

Kinetin stops the effects of Parkinson's disease on brain cells, say scientists

Scientists uncover potential drug target for effective therapy against bacterial disease brucellosis

Researchers develop new method that creates libraries of drug candidates, accelerate drug discovery

Preventive antibiotics for HIV patients lower risk of TB or death

Neurologists appear unaware of serious safety risks associated with anti-epilepsy drugs

A*STAR's SIgN discovers new strategy to develop universal dengue vaccine

Coalition with Innovative Life Sciences delivers best medicine in oncology for cancer patients

Preclinical study reveals pomalidomide shows promising results for treatment of CNS lymphoma

Perrigo Company and Teva Pharmaceutical launch generic equivalent to temozolomide

FDA: New drug Tivicay approved to treat HIV-1 infection

Bacterial strains that delay cell division might be used to design drugs that stop division entirely

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News